Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sten Stovall

London, UK
Sten Stovall is a London-based editor and writer with 40 years of experience in the field of journalism, including more than 20 years with Reuters and eight years with The Wall Street Journal/Dow Jones Newswires. He also has wide radio and television reporting experience and a solid network of contacts in the biopharma world. Sten is part of our team of specialist reporters, generating insightful features and analysis about R&D, product development, regulatory issues and industry trends for publications such as "The Pink Sheet", Scrip and IN VIVO.
Set Alert for Articles By Sten Stovall

Latest From Sten Stovall

CytomX’s Probody T-Cell Platform Produces Astellas Pact

Astellas of Japan and Cytomx of the US will deploy the latter’s Probody bispecific technology to design therapeutics that remain inactive until triggered by proteases in the tumor microenvironment, so that they bind selectively to tumors and leave healthy tissue alone.  

Deals Companies

Experts Say COVID-19 Battle Needs More Funding, Cooperation

Adequate funding and joined-up global cooperation are two top priorities needed to combat COVID-19, a panel of pharma executives told this year’s BIO-Europe Spring.

Coronavirus COVID-19 Clinical Trials

Bayer, Curadev Enter ‘STING’ Pact Exploring Inflammatory Disease

Bayer and Curadev entered a research collaboration and license agreement to develop novel STING antagonists targeting inflammatory disease.

Companies Commercial

Japan’s AGC Makes Agreed €240m Bid For MolMed

AGC of Japan is offering to buy cell and gene therapy specialist MolMed SPA in a deal worth up to €240m and backed by the biotech’s biggest shareholder, Silvio Berlusconi’s Fininvest.

Companies Commercial

Sweden Urges Pharma To Engage In AMR Initiative

Sweden is testing ‘pull incentives’ in hopes of finding viable reward mechanisms that would ensure adequate access to important antibiotics to meet the Scandinavian country’s domestic internal needs.

Companies Regulation

UK Experimental AMR Payment Program “On Track”

Designers of the UK’s experimental antibiotic payment system aim to identify two drugs later this year which will then undergo a novel technology assessment in 2021.

Market Access Infectious Diseases
See All
UsernamePublicRestriction

Register